Skip to main content

Juan Jose Gonzalez Lopez

I am a clinical microbiologist and I work in the Microbiology Department at the Vall d'Hebron University Hospital. I am also associate professor in the Department of Genetics and Microbiology at the Autonomous University of Barcelona and head of the Microbiology Research Group at the Vall d'Hebron Research Institute.

Institutions of which they are part

Head of group
Microbiology
Vall Hebron Institut de Recerca
Biologist
Microbiology
Cross-departmental services

Juan Jose Gonzalez Lopez

Institutions of which they are part

Head of group
Microbiology
Vall Hebron Institut de Recerca
Biologist
Microbiology
Cross-departmental services

I am a clinical microbiologist and I work in the Microbiology Department at the Vall d'Hebron University Hospital. I am also associate professor in the Department of Genetics and Microbiology at the Autonomous University of Barcelona and head of the Microbiology Research Group at the Vall d'Hebron Research Institute.

My professional work is divided into three fundamental lines which are assistance, teaching and research.

In terms of assistance, I have been working as a clinical microbiologist in the Microbiology Service since 2010 where I am currently leading the areas of bacterial identification and antibiograms.

Regarding the teaching aspect, I am a professor of the Degree of Medicine and the Degree of Microbiology at the Vall d'Hebron Campus of the Autonomous University of Barcelona. Likewise, I participate as a teacher in different master's degrees related to the field of microbiology and infectious diseases.

Regarding the research work, I am the head of the Microbiology Research Group at the Vall d'Hebron Research Institute. My research career has focused mainly on the study of the mechanisms of action and resistance to antimicrobials, on the molecular characterization of multidrug resistant bacterial populations and on the study of the mechanisms of bacterial pathogenicity.

Recently I have also started to work in new fields including the search for new therapeutic strategies against multidrug-resistant bacteria, the study of the populations and evolution of Bordetella pertussis and Neisseria meningitidis and the study of molecular mechanisms involved in sepsis, as well as in the development and validation of new diagnostic tools for infectious diseases.

Research lines

Microorganisms that cause vaccine-preventable diseases

Vaccines confer active immunoprotection, which is why they constitute one of the medical instruments that have contributed the most to the prevention of infectious diseases, estimating that around 2.5 million deaths are avoided annually thanks to them. The significant decrease in the incidence of diseases such as diphtheria, tetanus, poliomyelitis, invasive meningococcal disease or whooping cough, among others, or even the eradication of smallpox, is clear proof of their effectiveness. Despite this, in recent years a reemergence of certain infections that can be prevented by vaccination and that are caused by specific bacteria have been detected. Some examples of these bacteria are Neisseria meningitidis, which causes invasive meningococcal disease, or Bordetella pertussis, which produces whooping cough.


The VHIR microbiology research group is working on the study of the microbiological factors that may be conditioning the reemergence of these infections, as well as the characteristics of the patients who suffer from them and that may contribute to their acquisition and development. To this end, we work on the genomic characterization of bacterial populations such as N. meningitidis or B. pertussis through state-of-the-art technologies that allow us to monitor the evolution and adaptation of circulating clones in our environment, with the aim of early identification of the appearance of high-risk clones for public health, the rapid detection of the existence of transmission clusters between people, the emergence of strains not covered by currently used vaccines, and the identification of strains resistant to first- and second-line antimicrobial treatments, with the aim of in order to be able to design optimal measures to prevent the acquisition of these diseases, reduce their dissemination and optimize antimicrobial treatments.


Competitive projects that are currently being developed in this line of work:


Secuenciación de nueva generación para el estudio de la dinámica poblacional, adaptación e identificación de nuevos antígenos vacunales de B. pertussis y B. holmesii

PI: Juan José González López

Collaborators: Albert Moreno Mingorance

Financing entity: Instituto de Salud Carlos III

Financing: 82400

Reference: FI19/00315

Duration: 01/01/2020 - 31/12/2023


Secuenciación de nueva generación para el estudio de la dinámica poblacional, adaptación e identificación de nuevos antígenos vacunales de B. pertussis y B. holmesii. Estudio PERT-ESP-VAC

PI: Juan José González López

Collaborators: María Teresa Martín Gómez, Gema Codina Grau, Carlos Rodrigo Gonzalo de Liria, Alba Mir Cros, Thais Cornejo Sánchez, Sonia Maria Uriona Tuma

Financing entity: Instituto de Salud Carlos III

Financing: 111320

Reference: PI18/00703

Duration: 01/01/2019 - 30/06/2023


Caracterización de Neisseria meningitidis tras la introducción de la vacuna frente al serogrupo B e identificación de factores predisponentes para la enfermedad meningocócica invasiva

PI: Juan José González López

Collaborators: Manuel Hernández González, José Ángel Rodrigo Pendás, Aina Aguiló Cucurull, Alba Mir Cros, Albert Moreno Mingorance, Thais Cornejo Sánchez, Andrea Martín Nalda

Financing entity: Instituto de Salud Carlos III

Financing: 123420

Reference: PI21/00132

Duration: 01/01/2022 - 31/12/2024


IP: Juan Jose Gonzalez Lopez

Antimicrobial Resistance

Antimicrobial resistance is one of the main public health problems recognized by the main public health and sanitary agencies. Enterobacters such as Escherichia coli and Klebsiella pneumoniae, and other bacterial species such as Pseudomonas aeruginosa or Staphylococcus aureus are among the main pathogens causing infections and deaths associated with antimicrobial resistance.


Our research group works on the study of the mechanisms of action and resistance to antimicrobials of these and other bacteria of clinical interest, as well as the study of the mobile genetic elements where their resistance determinants can be found and possible therapeutic alternatives that can be considered to treat the infections they produce. Likewise, we work on the development, application and implementation of state-of-the-art processes, analysis and technologies that allow us to identify the molecular epidemiology, distribution and population structure of multi-resistant bacteria in order to early detect the emergence of high-risk epidemiological clones that can be transferred between patients, producing infections and/or outbreaks related to healthcare.

IP: Juan Jose Gonzalez Lopez, María Nieves Larrosa Escartin

Sepsis

IP: María Nieves Larrosa Escartin, Juan Jose Gonzalez Lopez

Projects

BIOBANCOS Y BIOMODELOS

IP: Isabel Novoa Garcia
Collaborators: Joaquim Vives Armengol, Anna Duarri Piqué, Eva Colas Ortega, Oriol Bestard Matamoros, Marta Rosal Fontana, Carmen Espejo Ruiz, Marielle Esteves Coelho, Juan Jose Gonzalez Lopez, Sheyla Pascual Martín, Alejandro Tomasello Weitz
Funding agency: Instituto de Salud Carlos III
Funding: 137460
Reference: PT23/00040
Duration: 01/01/2024 - 31/12/2026

Screening of new precision antibiotics for the treatment of multiresistant infections (ABPATHFINDER)

IP: Juan Jose Gonzalez Lopez
Collaborators: María Nieves Larrosa Escartin, Alba Mir Cros, Albert Moreno Mingorance
Funding agency: Fundació Institut Bioenginyeria de Catalunya
Funding: 0.01
Reference: D7357
Duration: 02/01/2023 - 31/12/2024

AMBROSIA: Multiplexed Plasmo-Photonic Biosensing Platform For Rapid And Intelligent Sepsis Diagnosis At The PointOf-Care

IP: Juan Jose Gonzalez Lopez
Collaborators: Juan Carlos Ruiz Rodriguez, Sira Rodrigo Bosch
Funding agency: EUROPEAN COMMISSION
Funding: 269812
Reference: AMBROSIA_HE-CL4_22_DIGI-EMERG01
Duration: 01/01/2023 - 31/12/2026

Caracterización de Neisseria meningitidis tras la introducción de la vacuna frente al serogrupo B e identificación de factores predisponentes para la enfermedad meningocócica invasiva.

IP: Juan Jose Gonzalez Lopez
Collaborators: Judit Álvarez González, Josep Roca Grande
Funding agency: Instituto de Salud Carlos III
Funding: 60000
Reference: INT22/00083
Duration: 01/01/2023 - 31/12/2024

Related news

The new diagnostic method, designed for use in endemic regions, combines a mobile application with a low-cost robotic microscope.

The European network EUPertStrain celebrates its annual meeting, focused on the study of the evolution of Bordetella pertussis, the bacterium responsible for this disease that can be very serious in children under one year.

The Vall d'Hebron work has shown that people vaccinated with Pfizer or Moderna have specific memory T lymphocytes against SARS-CoV-2 in the lung months after vaccination.

Related professionals

Ana Gallego Cortes

Ana Gallego Cortes

Predoctoral researcher
Infectious Diseases
Read more
Maider Arando Lasagabaster

Maider Arando Lasagabaster

Infectious Diseases
Read more
Joaquin Castillo Justribo

Joaquin Castillo Justribo

Postdoctoral researcher
Clinical Neuroimmunology
Read more
Barbara Citoler Naval

Barbara Citoler Naval

Research technician
Psychiatry, Mental Health and Addictions
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.